According to the research report titled ‘CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen; By Indication; By Regions: Segment Forecast, 2020 – 2026’, available with Market Study Report, global CAR-T cell therapy market is reckoned to witness a y-o-y growth rate of 34.5% CAGR during the forecast period, subsequently accounting for USD 8.92 billion by the year 2026.
 

Surging investments in this business domain coupled with focus among major companies towards innovative product launches, mergers & acquisitions, and other business-centric approaches are some of the key factors driving the growth of global CAR-T cell therapy market. 
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2963751/
 

For those unversed, a CAR-T cell therapy is a widely used solution which utilizes an individual’s immune cells to treat cancer. The white blood cells are extracted, reengineered, and injected again into the patient in order to counter malignant cells. CAR-T cell therapy has been gaining significant momentum in recent past for cancer treatment, which in turn is also stimulating the overall industry outlook.
 

In terms of indication type, the report states that Diffuse Large B-Cell Lymphoma (DLBCL) segment currently accounts for the largest revenue share in the overall market. However, global CAR-T cell therapy size from Multiple Myeloma (MM) segment is predicted to expand with 80% CAGR during the forecast period.
 

Considering the geographical landscape, the report cites that U.S. is one of the major revenue generators for worldwide CAR-T cell therapy industry. Escalating R&D investments, favorable regulatory approval system, increasing awareness regarding cancer management and innovative therapy launches are facilitating the business scenario in the United States.
 

Europe and Asia-Pacific are also likely to generate lucrative returns for the overall market in the ensuing years.
 

The competitive dynamics of global CAR-T cell therapy market are defined by companies such as Servier Laboratories, Sangamo Therapeutics Inc., Pfizer Inc., Novartis International AG, Noile-Immune Biotech Inc., Nanjing Legend Biotechnology Co. Ltd., Merck Group, Johnson & Johnson., Intellia Therapeutics, Gilead Sciences Inc., Celyad Oncology, Cellectis, Celgene Corporation, Caribou Biosciences Inc., bluebird bio Inc., Bellicum Pharmaceuticals Inc., and Amgen Inc. among others.